Key points from article :
Elon Musk's startup Neuralink has achieved a significant milestone with its brain-computer interface (BCI) technology, receiving FDA breakthrough device designation for its new implant, Blindsight. This implant is designed to restore vision to individuals who are blind, even those who have lost sight in both eyes or have damaged optic nerves. By implanting a microelectrode array into the brain's visual cortex, Blindsight stimulates neurons to provide visual images. Musk notes that early users can expect low-resolution vision, but the technology has the potential to surpass natural vision and even allow perception beyond visible light, such as infrared or ultraviolet.
This breakthrough is part of a larger effort by Neuralink to push the boundaries of BCIs. The company is currently conducting the PRIME study, a clinical trial aimed at helping people with quadriplegia use digital devices through thought alone. Neuralink has already had success with a patient using its BCI to play video games and chess after a successful implant.
Neuralink’s long-term vision is to develop a platform that interfaces with the entire brain, enabling a wide range of functions. Other companies, such as Neurable, are also advancing in the field of neurotechnology, focusing on improving cognitive performance and brain health in collaboration with precision health companies.
